Stocks · News reference
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Lakewood-Amedex Biotherapeutics doses its first Phase 2a patient with Nu-3 Gel for mildly infected diabetic foot ulcers and drug resistance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders
To our shareholders,The second quarter of 2026 represented a transformational period in the evolution of Lakewood-Amedex Biotherapeutics. We successfully transitioned to a Nasdaq-listed public company, significantly
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. 4,512,400 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,512,400 shares of common stock, par value $0.0001 per share, of Lakewood-Amedex